Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy of mature B cells with a characteristic clinical presentation but a variable clinical course. The rearranged immunoglobulin (Ig) genes of CLL cells may be either germ-line in sequence or somatically mutated. Lack of Ig mutations defined a distinctly worse prognostic group of CLL patients raising the possibility that CLL comprises two distinct diseases. Using genomic-scale gene expression profiling, we show that CLL is characterized by a common gene expression “signature,” irrespective of Ig mutational status, suggesting that CLL cases share a common mechanism of transformation and/or cell of origin. Nonetheless, the expression of hundreds of other genes correlated with the Ig mutational status, including many genes that are modulated in expression during mitogenic B cell receptor signaling. These genes were used to build a CLL subtype predictor that may help in the clinical classification of patients with this disease.

[1]  G. Widhopf,et al.  Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells1 , 2001, The Journal of Immunology.

[2]  K. Rajewsky,et al.  CD5‐positive B cells in healthy elderly humans are a polyclonal B cell population , 2000, European journal of immunology.

[3]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[4]  R Grosschedl,et al.  Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. , 2000, Immunity.

[5]  J. D. Di Santo,et al.  Tyrosine kinase SYK: essential functions for immunoreceptor signalling. , 2000, Immunology today.

[6]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[7]  John Calvin Reed,et al.  p21-Activated Kinase 1 Phosphorylates the Death Agonist Bad and Protects Cells from Apoptosis , 2000, Molecular and Cellular Biology.

[8]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[9]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[10]  I. Dunham,et al.  Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. , 1999, The Journal of investigative dermatology.

[11]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[12]  A. Weiss,et al.  The Syk family of protein tyrosine kinases in T‐cell activation and development , 1998, Immunological reviews.

[13]  Juswinder Singh,et al.  Identification of a frizzled‐like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases , 1998, Protein science : a publication of the Protein Society.

[14]  Klaus Rajewsky,et al.  Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.

[15]  L. Langeberg,et al.  Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein , 1997, Current Biology.

[16]  L. Rassenti,et al.  Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. , 1997, Journal of immunology.

[17]  L. Rassenti,et al.  Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. , 1996, Blood.

[18]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[19]  C. Auffray,et al.  The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. , 1996, Genomics.

[20]  E. Calleja,et al.  Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. , 1996, Blood.

[21]  H. Mellstedt,et al.  Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro. , 1994, Leukemia.

[22]  Klaus Rajewsky,et al.  Intraclonal generation of antibody mutants in germinal centres , 1991, Nature.

[23]  J. Binet,et al.  Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. , 1990, Blood.

[24]  N. Chiorazzi,et al.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia , 1989, The Journal of experimental medicine.

[25]  P. Lydyard,et al.  Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. , 1988, Journal of autoimmunity.

[26]  Tao Bai,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use , 2001 .

[27]  Ash A. Alizadeh,et al.  The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.

[28]  R. Kucherlapati,et al.  AICL: a new activation-induced antigen encoded by the human NK gene complex , 1997, Immunogenetics.

[29]  J. Cambier,et al.  Signal transduction by the B cell antigen receptor and its coreceptors. , 1994, Annual review of immunology.